Annual ROE
68.17%
-52.27%-43.40%
31 December 2023
Summary:
Galectin Therapeutics annual return on equity is currently 68.17%, with the most recent change of -52.27% (-43.40%) on 31 December 2023. During the last 3 years, it has risen by +165.16% (+170.29%). GALT annual ROE is now -99.53% below its all-time high of 14.51 thousand%, reached on 31 December 2006.GALT ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
58.93%
-8.08%-12.06%
30 September 2024
Summary:
Galectin Therapeutics quarterly return on equity is currently 58.93%, with the most recent change of -8.08% (-12.06%) on 30 September 2024. Over the past year, it has dropped by -35.40% (-37.53%). GALT quarterly ROE is now -99.83% below its all-time high of 34.48 thousand%, reached on 30 September 2011.GALT Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.4% | -37.5% |
| 3 y3 years | +170.3% | +132.5% |
| 5 y5 years | +133.8% | +251.0% |
GALT ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -43.4% | +105.8% | -96.0% | +109.8% |
| 5 y | 5 years | -43.4% | +105.8% | -96.0% | +109.8% |
| alltime | all time | -99.5% | +105.0% | -99.8% | +104.6% |
Galectin Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | 58.93%(-12.1%) |
| June 2024 | - | 67.01%(-4.7%) |
| Mar 2024 | - | 70.34%(-12.3%) |
| Dec 2023 | 68.17%(-43.4%) | 80.17%(-15.0%) |
| Sept 2023 | - | 94.33%(-12.3%) |
| June 2023 | - | 107.54%(-25.1%) |
| Mar 2023 | - | 143.67%(-29.7%) |
| Dec 2022 | 120.44%(-110.3%) | 204.23%(-40.6%) |
| Sept 2022 | - | 343.87%(-76.7%) |
| June 2022 | - | 1477.79%(-346.7%) |
| Mar 2022 | - | -598.95%(+131.6%) |
| Dec 2021 | -1166.93%(+1103.1%) | -258.63%(+42.7%) |
| Sept 2021 | - | -181.18%(+44.3%) |
| June 2021 | - | -125.52%(+32.7%) |
| Mar 2021 | - | -94.60%(+36.6%) |
| Dec 2020 | -96.99%(+232.6%) | -69.27%(+30.9%) |
| Sept 2020 | - | -52.90%(+31.5%) |
| June 2020 | - | -40.24%(+31.7%) |
| Mar 2020 | - | -30.56%(-11.8%) |
| Dec 2019 | -29.16%(-85.5%) | -34.63%(-11.3%) |
| Sept 2019 | - | -39.03%(-35.1%) |
| June 2019 | - | -60.14%(-59.4%) |
| Mar 2019 | - | -147.97%(-24.7%) |
| Dec 2018 | -201.51%(-85.2%) | -196.53%(-16.1%) |
| Sept 2018 | - | -234.34%(-35.9%) |
| June 2018 | - | -365.66%(-27.6%) |
| Mar 2018 | - | -504.74%(+50.1%) |
| Dec 2017 | -1360.85%(+662.8%) | -336.22%(+37.3%) |
| Sept 2017 | - | -244.80%(+30.2%) |
| June 2017 | - | -187.99%(+16.0%) |
| Mar 2017 | - | -162.13%(+10.0%) |
| Dec 2016 | -178.41%(+123.2%) | -147.35%(+21.9%) |
| Sept 2016 | - | -120.83%(+4.3%) |
| June 2016 | - | -115.86%(+17.4%) |
| Mar 2016 | - | -98.72%(+21.1%) |
| Dec 2015 | -79.95%(+41.7%) | -81.50%(+8.0%) |
| Sept 2015 | - | -75.43%(+25.6%) |
| June 2015 | - | -60.05%(+15.3%) |
| Mar 2015 | - | -52.10%(+3.4%) |
| Dec 2014 | -56.44%(-61.6%) | -50.39%(-10.5%) |
| Sept 2014 | - | -56.29%(-20.7%) |
| June 2014 | - | -71.02%(-30.1%) |
| Mar 2014 | - | -101.62%(-45.7%) |
| Dec 2013 | -146.93%(+20.2%) | -187.05%(+2.4%) |
| Sept 2013 | - | -182.69%(-13.7%) |
| June 2013 | - | -211.75%(+4.7%) |
| Mar 2013 | - | -202.34%(+18.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | -122.21%(-50.8%) | -170.45%(-23.4%) |
| Sept 2012 | - | -222.41%(-5.8%) |
| June 2012 | - | -236.13%(-27.0%) |
| Mar 2012 | - | -323.27%(-55.6%) |
| Dec 2011 | -248.24%(-174.7%) | -728.27%(-102.1%) |
| Sept 2011 | - | 34.48 K%(+4290.7%) |
| June 2011 | - | 785.27%(+153.2%) |
| Mar 2011 | - | 310.16%(+82.2%) |
| Dec 2010 | 332.29%(+98.9%) | 170.20%(+22.6%) |
| Sept 2010 | - | 138.88%(+2.9%) |
| June 2010 | - | 134.98%(-15.0%) |
| Mar 2010 | - | 158.79%(-25.7%) |
| Dec 2009 | 167.05%(-75.1%) | 213.70%(-30.1%) |
| Sept 2009 | - | 305.87%(-20.4%) |
| June 2009 | - | 384.04%(-6.3%) |
| Mar 2009 | - | 410.03%(+53.8%) |
| Dec 2008 | 671.86%(+108.3%) | 266.53%(+31.4%) |
| Sept 2008 | - | 202.90%(-32.7%) |
| June 2008 | - | 301.37%(-7.6%) |
| Mar 2008 | - | 326.31%(-69.7%) |
| Dec 2007 | 322.61%(-97.8%) | 1075.91%(-81.7%) |
| Sept 2007 | - | 5879.01%(-2789.5%) |
| June 2007 | - | -218.59%(-291.3%) |
| Mar 2007 | - | 114.25%(-26.1%) |
| Dec 2006 | 14.51 K%(-8046.6%) | 154.52%(-75.2%) |
| Sept 2006 | - | 622.68%(-148.6%) |
| June 2006 | - | -1280.29%(+217.1%) |
| Mar 2006 | - | -403.80%(+279.8%) |
| Dec 2005 | -182.64%(+157.1%) | -106.33%(+19.1%) |
| Sept 2005 | - | -89.31%(+20.7%) |
| June 2005 | - | -74.00%(+8.4%) |
| Mar 2005 | - | -68.28%(-12.9%) |
| Dec 2004 | -71.05%(+11.2%) | -78.37%(+1.5%) |
| Sept 2004 | - | -77.19%(-17.1%) |
| June 2004 | - | -93.08%(-19.4%) |
| Mar 2004 | - | -115.55%(-2.7%) |
| Dec 2003 | -63.92%(-71.9%) | -118.72%(-30.1%) |
| Sept 2003 | - | -169.89%(-21.7%) |
| June 2003 | - | -217.03%(-20.6%) |
| Mar 2003 | - | -273.19%(-32.5%) |
| Dec 2002 | -227.57%(-30.3%) | -404.55%(-34.7%) |
| Sept 2002 | - | -619.78%(-21.4%) |
| June 2002 | - | -788.03%(-35.9%) |
| Mar 2002 | - | -1229.82%(+10.8%) |
| Dec 2001 | -326.56% | -1110.22%(-188.6%) |
| Sept 2001 | - | 1253.07%(+1346.8%) |
| June 2001 | - | 86.61% |
FAQ
- What is Galectin Therapeutics annual return on equity?
- What is the all time high annual ROE for Galectin Therapeutics?
- What is Galectin Therapeutics annual ROE year-on-year change?
- What is Galectin Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly ROE year-on-year change?
What is Galectin Therapeutics annual return on equity?
The current annual ROE of GALT is 68.17%
What is the all time high annual ROE for Galectin Therapeutics?
Galectin Therapeutics all-time high annual return on equity is 14.51 K%
What is Galectin Therapeutics annual ROE year-on-year change?
Over the past year, GALT annual return on equity has changed by -52.27% (-43.40%)
What is Galectin Therapeutics quarterly return on equity?
The current quarterly ROE of GALT is 58.93%
What is the all time high quarterly ROE for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly return on equity is 34.48 K%
What is Galectin Therapeutics quarterly ROE year-on-year change?
Over the past year, GALT quarterly return on equity has changed by -35.40% (-37.53%)